Skye Bioscience, Inc. (SKYE) Earnings History
Net Loss14 years of earnings data (2012–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Skye Bioscience, Inc. (SKYE) Earnings Overview
As of June 22, 2026, Skye Bioscience, Inc. (SKYE) reported trailing twelve-month net income of -$57M, reflecting -93.2% year-over-year growth. The company earned $-1.44 per diluted share over the past four quarters.
Looking at the long-term picture, SKYE's historical earnings data spans multiple years. The company achieved its highest annual net income of $1M in fiscal 2019.
Skye Bioscience, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ATAI (-$663M net income, -16142.0% margin), CMPS (-$179M net income), MNMD (-$238M net income), SKYE has comparable earnings metrics. Compare SKYE vs ATAI →
SKYE Earnings vs Peers
Earnings metrics vs comparable public companies
SKYE Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$56M | -110.5% | -$58M | $-1.41 | - | - |
| 2024 | -$27M | +29.4% | -$30M | $-0.73 | - | - |
| 2023 | -$38M | -93.2% | -$35M | $-5.37 | - | - |
| 2022 | -$19M | -128.6% | -$18M | $-8.77 | - | - |
| 2021 | -$9M | -29.9% | -$8M | $-5.00 | - | - |
| 2020 | -$7M | -723.7% | -$6M | $-7.46 | - | - |
| 2019 | $1M | +105.5% | -$7M | $1.98 | - | - |
| 2018 | -$19M | -520.4% | -$5M | $-36.51 | - | - |
| 2017 | -$3M | +2.6% | -$4M | $-25.62 | - | - |
| 2016 | -$3M | +34.4% | -$4M | $-39.90 | - | - |
| 2015 | -$5M | -77.1% | -$4M | $-70.93 | - | - |
| 2014 | -$3M | -2170.7% | -$3M | $-65.08 | - | - |
| 2013 | $-120,403 | -2770.3% | $-7,242 | $-3.52 | -35.4% | -2.1% |
| 2012 | $4,509 | - | $4,117 | $0.13 | 27.8% | 25.3% |
Download Data
Export SKYE earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
14+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SKYE — Frequently Asked Questions
Quick answers to the most common questions about buying SKYE stock.
What is SKYE earnings per share (EPS)?
SKYE trailing twelve-month (TTM) diluted EPS is $-1.44, reflecting -93.2% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2012 to 2025 is available in the table on this page.
What is Skye Bioscience, Inc.'s net income?
Skye Bioscience, Inc. (SKYE) trailing twelve-month net income is $-57M as of 2025. Earnings declined -93.2% year-over-year.
Is SKYE profitable?
SKYE is not currently profitable on a TTM basis, reporting a net loss of $-57M. Net margin is N/A. Investors should monitor for a return to profitability.
What is SKYE's earnings growth rate?
SKYE compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2012 to 2025.
What are SKYE's profit margins?
Skye Bioscience, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -126.8%.
Is SKYE growing earnings?
SKYE earnings are declining — EPS fell -93.2% year-over-year. TTM net income dropped to $-57M. This contrasts with the 5-year CAGR of N/A.
What was SKYE's best earnings year?
Skye Bioscience, Inc.'s highest annual net income on record is $1M, achieved in fiscal year 2019. Earnings history on this page spans 2012 to 2025 and includes all annual and quarterly figures.
What were SKYE's earnings last quarter?
SKYE's most recent reported quarter was Q1 2026. Net income was $-13M with diluted EPS of $-0.32. For a full breakdown of all quarters, see the quarterly earnings table on this page.